Business Description
Hanmi Pharm Co Ltd
NAICS : 325412
SIC : 2834
ISIN : KR7128940004
Compare
Compare
Traded in other countries / regions
128940.Korea IPO Date
2010-07-30Description
Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.48 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | 1.42 | |||||
| Interest Coverage | 9.92 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 4.93 | |||||
| Beneish M-Score | -2.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.4 | |||||
| 3-Year EBITDA Growth Rate | 44.7 | |||||
| 3-Year EPS without NRI Growth Rate | 100 | |||||
| 3-Year FCF Growth Rate | 23.6 | |||||
| 3-Year Book Growth Rate | 9.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.92 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 7.95 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.37 | |||||
| 9-Day RSI | 62.12 | |||||
| 14-Day RSI | 60.18 | |||||
| 6-1 Month Momentum % | -15.38 | |||||
| 12-1 Month Momentum % | -2.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | |||||
| Quick Ratio | 0.66 | |||||
| Cash Ratio | 0.36 | |||||
| Days Inventory | 155.58 | |||||
| Days Sales Outstanding | 35.82 | |||||
| Days Payable | 23.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.24 | |||||
| Dividend Payout Ratio | 0.05 | |||||
| 3-Year Dividend Growth Rate | 2 | |||||
| Forward Dividend Yield % | 0.24 | |||||
| 5-Year Yield-on-Cost % | 0.27 | |||||
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | 2.44 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.79 | |||||
| Operating Margin % | 16.99 | |||||
| Net Margin % | 11.75 | |||||
| FCF Margin % | 12.63 | |||||
| ROE % | 18.81 | |||||
| ROA % | 9.58 | |||||
| ROIC % | 13.33 | |||||
| 3-Year ROIIC % | 1466.72 | |||||
| ROC (Joel Greenblatt) % | 24.55 | |||||
| ROCE % | 21.77 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.67 | |||||
| Forward PE Ratio | 21.33 | |||||
| PE Ratio without NRI | 20.44 | |||||
| Price-to-Owner-Earnings | 20.43 | |||||
| PEG Ratio | 0.94 | |||||
| PS Ratio | 2.55 | |||||
| PB Ratio | 3.78 | |||||
| Price-to-Tangible-Book | 4.21 | |||||
| Price-to-Free-Cash-Flow | 20.16 | |||||
| Price-to-Operating-Cash-Flow | 15.79 | |||||
| EV-to-EBIT | 16.21 | |||||
| EV-to-EBITDA | 11.89 | |||||
| EV-to-Revenue | 2.78 | |||||
| EV-to-FCF | 21.53 | |||||
| Price-to-Projected-FCF | 2.73 | |||||
| Price-to-DCF (Earnings Based) | 1.68 | |||||
| Price-to-DCF (FCF Based) | 0.6 | |||||
| Price-to-Median-PS-Value | 0.8 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.84 | |||||
| Price-to-Graham-Number | 1.98 | |||||
| Earnings Yield (Greenblatt) % | 6.17 | |||||
| FCF Yield % | 4.84 | |||||
| Forward Rate of Return (Yacktman) % | 22.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hanmi Pharm Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 1,568,781.092 | ||
| EPS (TTM) (â‚©) | 14534.02 | ||
| Beta | 0.47 | ||
| Volatility % | 28.68 | ||
| 14-Day RSI | 60.18 | ||
| 14-Day ATR (â‚©) | 13347.354329 | ||
| 20-Day SMA (â‚©) | 304025 | ||
| 12-1 Month Momentum % | -2.76 | ||
| 52-Week Range (â‚©) | 258000 - 377000 | ||
| Shares Outstanding (Mil) | 12.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hanmi Pharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hanmi Pharm Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hanmi Pharm Co Ltd Frequently Asked Questions
What is Hanmi Pharm Co Ltd(XKRX:128940)'s stock price today?
The current price of XKRX:128940 is â‚©322500.00. The 52 week high of XKRX:128940 is â‚©377000.00 and 52 week low is â‚©258000.00.
When is next earnings date of Hanmi Pharm Co Ltd(XKRX:128940)?
The next earnings date of Hanmi Pharm Co Ltd(XKRX:128940) is .
Does Hanmi Pharm Co Ltd(XKRX:128940) pay dividends? If so, how much?
The Dividend Yield %  of Hanmi Pharm Co Ltd(XKRX:128940) is 0.24% (As of Today), Highest Dividend Payout Ratio of Hanmi Pharm Co Ltd(XKRX:128940) was 0.3. The lowest was 0.04. And the median was 0.1. The  Forward Dividend Yield % of Hanmi Pharm Co Ltd(XKRX:128940) is 0.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers